Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

By sjmartinez • March 28, 2023

Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023 Mar 18;15:265-275. doi: 10.2147/CMAR.S341468. PMID: 36969544; PMCID: PMC10032141.

Tags: gastric cancer, gastroesophageal junction cancer, Hematology/Oncology, immune checkpoint inhibition, immunotherapy, PD-L1, Publications

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]

Epigenetic age acceleration measures and chemotoxicity in older adults with early breast cancer

Ji J, Sun CL, Dale W, Kim H, Katheria V, Lee C, Smith C, Sun N, Ding YC, Neuhausen SL, Cohen HJ, Binder A, Sedrak[...]